|
|
|
|
|
|
Sponsors and Collaborators: |
University Health Network, Toronto Princess Margaret Hospital, Canada |
Information provided by: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT00259584 |
All patients with symptomatic malignant SVCO deemed suitable for treatment either with radiation therapy or by stenting will be eligible. They will receive whichever treatment is deemed most clinically appropriate. Symptomatic response, time to onset of palliation, duration of symptom control and survival will be assessed.
Condition | Intervention | Phase |
Superior Vena Cava Syndrome |
Behavioral: Management and Outcome of SVCO |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | A Prospective Longitudinal Study of the Management and Outcome of Superior Vena Caval Obstruction (SVCO) |
Estimated Enrollment: | 20 |
Study Start Date: | October 2001 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contact: Andrea Bezjak, MD | 416-946-2132 | andrea.bezjak@rmp.uhn.on.ca |
Canada, Ontario | |||||
University Health Network | Recruiting | ||||
Toronto, Ontario, Canada, M5G 2M9 | |||||
Contact: Andrea Bezjak, MD 416-946-2132 andrea.bezjak@rmp.uhn.on.ca | |||||
Principal Investigator: Andrea Bezjak, MD |
University Health Network, Toronto |
Princess Margaret Hospital, Canada |
Principal Investigator: | Andrea Bezjak, MD | Princess Margaret Hospital, Canada |
Study ID Numbers: | UHN REB 01-0770-C |
First Received: | November 28, 2005 |
Last Updated: | February 16, 2006 |
ClinicalTrials.gov Identifier: | NCT00259584 |
Health Authority: | Canada: Ethics Review Committee |
|
|